Catalent and S.Biomedics announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics’ allogeneic pluripotent stem-cell-derived ventral midbrain–specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson’s disease.

TED‑A9 represents S.Biomedics’ ambition to deliver a new class of regenerative medicine for patients with Parkinson’s disease. The program reflects years of development using S.Biomedics’ proprietary targeted embryonic stem cell differentiation (TED) platform and builds on the company’s growing clinical pipeline of stem‑cell–based therapies.

“Initiating our first U.S. clinical study, which is designed as a pivotal trial, represents a critical step toward delivering new treatment options to patients,” said Tony Kang, chief executive officer of S.Biomedics. “We are pleased to partner with Catalent, a global leader in cell therapy CDMO services, as we establish a scalable, GMP‑ready manufacturing foundation to support pivotal development and enable a potential path toward future commercialization, with the ultimate goal of bringing hope to patients and families affected by Parkinson’s disease worldwide.”

“Catalent’s advanced cell therapy development and manufacturing capabilities are designed to help innovators like S.Biomedics move confidently through pivotal studies toward commercial readiness,” said David McErlane, Group President, Biologics at Catalent. “We are proud to work together to build a robust, scalable foundation that can accelerate access to this promising therapy for patients and families worldwide.”

Catalent will leverage its global network and deep expertise in cell therapy development, analytical services, and GMP manufacturing to support TED-A9. Catalent’s integrated platforms and iPSC/ESC experience position the company to accelerate programs like TED-A9 from early development through clinical and commercial launch.